Logo image of DMAAR

DRUGS MADE IN AMERICA AC-RTS (DMAAR) Stock Price, Forecast & Analysis

USA - NASDAQ:DMAAR -

0.164 USD
-0.03 (-15.9%)
Last: 11/17/2025, 8:00:01 PM
Fundamental Rating

1

Taking everything into account, DMAAR scores 1 out of 10 in our fundamental rating. DMAAR was compared to 0 industry peers in the Unkown industry. DMAAR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DMAAR has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

DMAAR had negative earnings in the past year.
DMAAR Yearly Net Income VS EBIT VS OCF VS FCFDMAAR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2023 2024 -50K -100K -150K -200K -250K

1.2 Ratios

Industry RankSector Rank
ROA -0.12%
ROE -0.12%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMAAR Yearly ROA, ROE, ROICDMAAR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2023 2024 0 50 -50 100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DMAAR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAAR Yearly Profit, Operating, Gross MarginsDMAAR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for DMAAR has been reduced compared to 1 year ago.
DMAAR Yearly Shares OutstandingDMAAR Yearly Shares OutstandingYearly Shares Outstanding 2023 2024 20M 40M 60M
DMAAR Yearly Total Debt VS Total AssetsDMAAR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2023 2024 200K 400K 600K

2.2 Solvency

DMAAR has an Altman-Z score of 0.41. This is a bad value and indicates that DMAAR is not financially healthy and even has some risk of bankruptcy.
There is no outstanding debt for DMAAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.41
ROIC/WACCN/A
WACCN/A
DMAAR Yearly LT Debt VS Equity VS FCFDMAAR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2023 2024 -50K -100K -150K -200K

2.3 Liquidity

DMAAR has a Current Ratio of 0.17. This is a bad value and indicates that DMAAR is not financially healthy enough and could expect problems in meeting its short term obligations.
DMAAR has a Quick Ratio of 0.17. This is a bad value and indicates that DMAAR is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.17
Quick Ratio 0.17
DMAAR Yearly Current Assets VS Current LiabilitesDMAAR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2024 200K 400K 600K

More info and screens

0

3. Growth

3.1 Past

EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DMAAR. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMAAR Price Earnings VS Forward Price EarningsDMAAR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAAR Per share dataDMAAR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

DMAAR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DRUGS MADE IN AMERICA AC-RTS

NASDAQ:DMAAR (11/17/2025, 8:00:01 PM)

0.164

-0.03 (-15.9%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-17 2025-11-17
Earnings (Next)03-18 2026-03-18
Inst Owners63.26%
Inst Owner Change-0.81%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap5.50M
Revenue(TTM)N/A
Net Income(TTM)-280.00K
AnalystsN/A
Price TargetN/A
Short Float %0.09%
Short Ratio0.43
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.02
P/tB 0.02
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS6.8
TBVpS6.8
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.12%
ROE -0.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.17
Quick Ratio 0.17
Altman-Z 0.41
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

DRUGS MADE IN AMERICA AC-RTS / DMAAR FAQ

What does DMAAR do?

Drugs Made In America Acquisition Corp. is a blank check company, which engages in the provision of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The company is headquartered in Fort Lauderdale, Florida. The company went IPO on 2025-01-28. The firm is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The firm intends to focus its search for businesses in the pharmaceutical industry. The firm has neither engaged in any operations nor generated any revenues.


What is the stock price of DRUGS MADE IN AMERICA AC-RTS today?

The current stock price of DMAAR is 0.164 USD. The price decreased by -15.9% in the last trading session.


How is the ChartMill rating for DRUGS MADE IN AMERICA AC-RTS?

DMAAR has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.